Trial Profile
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Lenalidomide (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 14 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Mar 2025.
- 14 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Mar 2025.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.